

Supplementary Table 2. Summary of sensitivity analysis for studies with parallel design

Outcomes and subgroups	No. of comparisons	No. of patients		Mean difference between automated insulin delivery systems and other insulin therapy (95% CI), %	Z value for overall effect	P value for overall effect	I ² , %	Chi ²	df	P value	Tau ²
		Intervention	Control								
TIR	22	1,245	962	12.290 (9.441 to 15.139)	8.45	<0.001	84.7	136.86	21	<0.001	36.6519
TBR	22	1,245	962	-0.794 (-1.242 to -0.345)	-3.47	0.001	83.2	125.26	21	<0.001	0.7736
TAR	18	1,187	893	-11.495 (-14.708 to -8.282)	-7.012	<0.001	83.9	105.83	17	<0.001	38.5441
CV	19	1,064	785	-1.079 (-2.102 to -0.055)	-2.066	0.039	75.2	72.57	18	<0.001	3.5708
GRI	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
HbA1c	16	1,145	863	-0.413 (-0.516 to -0.311)	-7.907	<0.001	36.1	23.46	15	0.075	0.0147
Insulin dose	14	671	509	0.003 (-0.150 to 0.156)	0.037	0.970	36.8	20.55	13	0.082	0.0301

CI, confidence interval; TIR, time in range; TBR, time below range; TAR, time above range; CV, coefficient of variation; GRI, glycemia risk index; NA, not applicable; HbA1c, glycosylated hemoglobin.

Supplementary Table 3. Summary of publication bias for all outcomes by Egger's test

Outcome	T value	P value
TIR	1.28	0.204
TBR	-0.70	0.488
TAR	-0.82	0.418
CV	1.37	0.178
GRI	-1.00	0.373
HbA1c	-1.58	0.128
Insulin dose	-1.13	0.264
Severe hypoglycemia	1.91	0.072
Diabetic ketoacidosis	1.04	0.334

TIR, time in range; TBR, time below range; TAR, time above range; CV, coefficient of variation; GRI, glycemia risk index; HbA1c, glycosylated hemoglobin.